Zhao et al., 2019 - Google Patents
Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastomaZhao et al., 2019
View HTML- Document ID
- 7189108666366073837
- Author
- Zhao J
- Chen A
- Gartrell R
- Silverman A
- Aparicio L
- Chu T
- Bordbar D
- Shan D
- Samanamud J
- Mahajan A
- Filip I
- Orenbuch R
- Goetz M
- Yamaguchi J
- Cloney M
- Horbinski C
- Lukas R
- Raizer J
- Rae A
- Yuan J
- Canoll P
- Bruce J
- Saenger Y
- Sims P
- Iwamoto F
- Sonabend A
- Rabadan R
- Publication year
- Publication venue
- Nature medicine
External Links
Snippet
Immune checkpoint inhibitors have been successful across several tumor types; however, their efficacy has been uncommon and unpredictable in glioblastomas (GBM), where< 10% of patients show long-term responses. To understand the molecular determinants of …
- 238000009169 immunotherapy 0 title abstract description 48
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
- C12Q1/6886—Hybridisation probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
- G06Q50/10—Services
- G06Q50/22—Health care, e.g. hospitals; Social work
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/10—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhao et al. | Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma | |
| Färkkilä et al. | Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer | |
| Ny et al. | The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma | |
| Sun et al. | Dissecting spatial heterogeneity and the immune-evasion mechanism of CTCs by single-cell RNA-seq in hepatocellular carcinoma | |
| Liu et al. | Clinical implications of aberrant PD-1 and CTLA4 expression for cancer immunity and prognosis: a pan-cancer study | |
| Chemi et al. | Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse | |
| Chakravarthy et al. | Pan-cancer deconvolution of tumour composition using DNA methylation | |
| Kim et al. | Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer | |
| Formenti et al. | Radiotherapy induces responses of lung cancer to CTLA-4 blockade | |
| Rodrigues et al. | Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer | |
| Wang et al. | Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia | |
| Jiang et al. | Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trial | |
| Pan et al. | The molecular landscape of Asian breast cancers reveals clinically relevant population-specific differences | |
| Ma et al. | Simultaneous evolutionary expansion and constraint of genomic heterogeneity in multifocal lung cancer | |
| Bentham et al. | Using DNA sequencing data to quantify T cell fraction and therapy response | |
| Zhang et al. | B2M overexpression correlates with malignancy and immune signatures in human gliomas | |
| Panda et al. | Identifying a clinically applicable mutational burden threshold as a potential biomarker of response to immune checkpoint therapy in solid tumors | |
| Schulz et al. | Germline variants in the SEMA4A gene predispose to familial colorectal cancer type X | |
| Marsit et al. | DNA methylation array analysis identifies profiles of blood-derived DNA methylation associated with bladder cancer | |
| Ni et al. | Reproducible copy number variation patterns among single circulating tumor cells of lung cancer patients | |
| Zhang et al. | Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma | |
| Jäkel et al. | Genome-wide genetic and epigenetic analyses of pancreatic acinar cell carcinomas reveal aberrations in genome stability | |
| Boiarsky et al. | Single cell characterization of myeloma and its precursor conditions reveals transcriptional signatures of early tumorigenesis | |
| Sharma et al. | Validation of the DNA damage immune response signature in patients with triple-negative breast cancer from the SWOG 9313c trial | |
| Samuel et al. | Genome-wide DNA methylation analysis reveals epigenetic dysregulation of microRNA-34A in TP53-associated cancer susceptibility |